This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Walter, D. H. Articles by Zeiher, A. M. Search for Related Content PubMed PubMed Citation Articles by Walter, D. H. Articles by Zeiher, A. M.

Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation

^a Department of Internal Medicine IV, Division of Cardiology, University of Frankfurt, Frankfurt, Germany

View larger version (11K): [in a new window]   Figure 1 Relative risks for primary combined end point events (death, myocardial infarction, target vessel revascularization) within six-month follow-up according to the presence or absence of elevated C-reactive protein (CRP) levels (above median value 0.6 mg/dl) or presence or absence of statin treatment in patients following coronary stent implantation.

View larger version (18K): [in a new window]   Figure 2 Cumulative survival curves for primary combined end point events (death, myocardial infarction [MI], target vessel revascularization) within six-month follow-up according to the presence or absence of elevated C-reactive protein (CRP) levels (above median value 0.6 mg/dl) or presence and absence of statin treatment in patients following coronary stent implantation. The p value was obtained from the log-rank test.